Breaking News

MicroConstants Completes FDA Inspection

October 10, 2012

No observations or recommendations reported

MicroConstants, a bioanalytical and pharmacokinetic specialty CRO, has successfully completed a five-day inspection by the FDA for compliance with GLP regulations. The FDA inspected the company’s San Diego facility for overall GLP compliance and assessed lab areas and several method validations, three sample analysis projects, and a pharmacokinetic analysis report. The investigator reported zero findings, observations, or recommendations.

“MicroConstants aims to have one of the most comprehensive quality assurance programs in the industry,” said Jose Buenviaje, vice president of quality assurance and regulatory compliance at MicroConstants. “Annual examinations of our QA programs and bi-annual client surveys allow us to continually evaluate our current quality systems. This FDA inspection further confirms the quality of GLP-compliant services performed by MicroConstants.”

Related Compliance:

blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus